Amgen Inc (AMGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Amgen rose $1.94 (1.6%) to $125.79 on average volume. Throughout the day, 2,603,583 shares of Amgen exchanged hands as compared to its average daily volume of 3,161,500 shares. The stock ranged in a price between $124.20-$126.59 after having opened the day at $124.38 as compared to the previous trading day's close of $123.85. Other companies within the Drugs industry that increased today were: RXi Pharmaceuticals ( RXII), up 28.5%, Celladon ( CLDN), up 25.5%, Inovio Pharmaceuticals ( INO), up 15.5% and Tekmira Pharmaceuticals Corporation ( TKMR), up 12.9%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $93.1 billion and is part of the health care sector. Shares are up 8.2% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Five Prime Therapeutics ( FPRX), down 10.1%, Cardiome Pharma Corporation ( CRME), down 5.9%, Echo Therapeutics ( ECTE), down 5.7% and Fibrocell Science ( FCSC), down 5.7% , were all laggards within the drugs industry with Ariad Pharmaceuticals ( ARIA) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

What Do Trade Wars Mean for High Yield Bond Investors?

What Do Trade Wars Mean for High Yield Bond Investors?

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Oil Slips From Three-Year Peak After Trump Tweets Anger at OPEC

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

Swiss Franc Slides to Three-Year Low as U.S. Sanctions on Russian Oligarchs Bite

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know